Sugi Predict

Sugi Predict / Compounds / Glutarate

Glutarate

Glutarate

SCHEMBL162952

O=C(O)CCCC(=O)O.[SrH2]

nearest known ligand 0.92

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC22A6 Q4U2R8 2/20 0.92
▸ LMNA P02545 4/20 0.77
▸ TSHR P16473 6/20 0.71
▸ NFKB1 P19838 2/20 0.71
▸ PMP22 Q01453 1/20 0.71
▸ CAMK2A Q9UQM7 1/20 0.62
▸ ALKBH5 Q6P6C2 1/20 0.61
▸ SUCNR1 Q9BXA5 1/20 0.61
▸ EGLN1 Q9GZT9 1/20 0.61
▸ HDAC11 Q96DB2 4/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ GABRR3 A8MPY1 1/20 0.59
▸ GABRP O00591 1/20 0.59
▸ GABRD O14764 1/20 0.59
▸ HDAC3 O15379 1/20 0.59
▸ GABBR2 O75899 1/20 0.59
▸ CYP1A2 P05177 1/20 0.59
▸ THRB P10828 1/20 0.59
▸ GABRA1 P14867 1/20 0.59
▸ GABRB1 P18505 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutarate SCHEMBL6701735 0.96 — —
Glutarate SCHEMBL27601182 0.96 SLC22A6 (1.00) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL158774 0.96 SLC22A6 (1.00) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL7414 0.96 — —
Glutarate SCHEMBL106538 0.92 SLC22A6 (0.92) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL3687200 0.92 SLC22A6 (0.92) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL2067314 0.92 SLC22A6 (0.92) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL20876932 0.92 SLC22A6 (0.92) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL9805513 0.92 SLC22A6 (0.92) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL8618878 0.92 SLC22A6 (0.92) SLC22A6LMNATSHRNFKB1PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 — — US claimed
CN-106456662-A Compositions of pentosan polysulfate for oral administration and methods of use thereof 奥利金制药公司 2017-02-22 — — CN claimed
EP-3110427-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE Urigen Pharmaceuticals, Inc. (US) 2017-01-04 — — EP claimed
WO-2015127416-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE URIGEN PHARMACEUTICALS, INC. (US) 2015-08-27 — — WO claimed
US-8609616-B2 Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions OSTEOLOGIX A/S (DK) 2013-12-17 — — US claimed
US-20130071496-A1 CONTROLLED RELEASE COMPOSITION CONTAINING A STRONTIUM SALT OSTEOLOGIX A/S (DK) 2013-03-21 — — US claimed
EP-2416756-A2 STABLE PHARMACEUTICAL COMPOSITIONS WITH HIGH BIOAVAILIBILITY Bilgic, Mahmut (TR) 2012-02-15 — — EP claimed
US-20110269675-A1 STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS OSTEOLOGIX A/S 2011-11-03 — — US claimed
EP-2266584-A2 Composition with strontium and vitamin D for the prophylaxis and/or treatment of cartilage and/or bone conditions Osteologix A/S (DK) 2010-12-29 — — EP claimed
EP-1732575-B1 STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS OSTEOLOGIX AS (DK) 2010-12-29 — — EP claimed
US-20060216358-A1 Controlled release composition containing a strontium salt OSTEOLOGIX A/S (DK) 2006-09-28 — — US claimed
EP-1622630-A2 STRONTIUM COMBINATIONS FOR THE PROPHYLAXIS/TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS Osteologix A/S (DK) 2006-02-08 — — EP claimed
EP-1622629-A2 CONTROLLED RELEASE COMPOSITION CONTAINING A STRONTIUM SALT Osteologix A/S (DK) 2006-02-08 — — EP claimed
WO-2005123193-A2 TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN OSTEOLOGIX A/S (DK) 2005-12-29 — — WO claimed
WO-2005123130-A2 IMPROVED TREATMENTS OF RHEUMATIC AND ARTHRITIC DISEASES COMPRISING COMBINATIONS OF A 5-LIPOXYGENASE INHIBITOR OSTEOLOGIX A/S (DK) 2005-12-29 — — WO claimed
WO-2005123192-A2 IMPROVING PAIN TREATMENT WITH STRONTIUM COMBINATIONS OSTEOLOGIX A/S (DK) 2005-12-29 — — WO claimed
WO-2005123098-A2 PREVENTING GASTROINTESTINAL SIDE-EFFECTS WITH STRONTIUM SALTS OSTEOLOGIX A/S (DK) 2005-12-29 — — WO claimed
WO-2005082385-A1 STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS OSTEOLOGIX A/S (DK) 2005-09-09 — — WO claimed
WO-2004098618-A2 STRONTIUM COMBINATIONS FOR PROPHYLAXIS/TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS OSTEOLOGIX A/S (DK) 2004-11-18 — — WO claimed
WO-2004098617-A2 CONTROLLED RELEASE COMPOSITION CONTAINING A STRONTIUM SALT OSTEOLOGIX A/S (DK) 2004-11-18 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS SI, SLC20A1, SLC20A2 SLC22A6 23/4885LMNA 4376/4885TSHR 4340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.